Cantor Fitzgerald reiterates Neutral on Humana stock at $264

Humana (HUM) received a Cantor Fitzgerald $264 target (Neutral) while the stock trades at $396.75—~25% above the target—despite an underlying Medicaid shift (KY Medicaid revenue ~13.0% of total). Offsetting positives include an Illinois HealthChoice Medicaid contract covering all 102 counties tied to a ~$30B award for ~3.1M members, plus Louisiana enrollment support after UnitedHealth’s contract termination (Humana +51k enrollees QoQ). Off-balance, UBS kept Neutral with a $320 target citing utilization trends, and Humana plans to sell its minority stake in Gentiva for ~ $900M.

Analysis

The market is treating incremental Medicaid membership as growth, but the more important variable is margin quality. For a managed-care name already trading well above consensus target, a richer mix of state-funded lives usually deserves a lower multiple unless the bidding process proves structurally favorable; otherwise the extra top line can be value-destructive on ROIC. The Louisiana rate reset is the key near-term gate: enrollment wins there are only durable if reimbursement keeps pace with utilization, and that is where the bear case lives.

Second-order, the competitive signal is bigger than the company-specific print. If one incumbent can lose a contract and another can absorb the lives, that suggests churn is becoming a feature of Medicaid procurement, which tends to pressure everyone’s pricing discipline over time. That favors the most diversified operators less exposed to one or two states and hurts names that are increasingly underwriting earnings to public-sector contracts.

The Gentiva sale helps liquidity and simplifies the story, but it does not change the core issue: the equity is being asked to pay a premium for a business mix that is moving toward a lower-multiple segment. If medical cost trend or state bids come in even modestly worse than expected, the current valuation has room to compress quickly. The contrarian view is that the Street may be underestimating how much downside is already embedded if this Medicaid pivot fails to convert into margin expansion over the next 2-3 quarters.

Key Decisions for Investors

• Short HUM on strength above the current tape; use a 1-3 month put spread (e.g., 380/340 or similar) into the July 1 Louisiana rate-setting window. Risk/reward: defined downside with the first meaningful catalyst in weeks, not years.
• Pair trade: short HUM / long ELV for 1-2 quarters. Thesis: HUM is being valued like a higher-quality managed-care compounder even as its mix shifts toward lower-multiple Medicaid revenue; ELV offers cleaner diversification and less single-state sensitivity.
• Set a thesis stop on HUM if Louisiana rates come in clearly favorable or if the next earnings update shows Medicaid MLR improving by >100 bps versus current trend. That would signal the market is right to re-rate the enrollment gains.
• Watch for a failed bear trigger: if Illinois implementation starts with unexpectedly strong margin disclosure, cover the short quickly. Contract wins can look attractive on slide decks but often carry launch costs that only show up one or two quarters later.
• For more tactical traders, fade any post-news pop in HUM rather than chasing it. The asymmetry is better expressed after strength, when valuation is still anchored near the highs and the next catalyst is a reimbursement reset, not a growth surprise.